

AMENDMENTS TO THE CLAIMS

Please amend the claims as indicated below:

1-29 (Cancelled).

30. (Previously presented) The method of Claim 41, wherein R_a is $-OR_1$.

31. (Previously presented) The method of Claim 41, wherein R_a is $-OCOR_1$.

32. (Previously presented) The method of Claim 41, wherein the neovascularization is ocular neovascularization.

33. (Previously presented) The method of Claim 30, wherein the neovascularization is ocular neovascularization.

34. (Previously presented) The method of Claim 31, wherein the neovascularization is ocular neovascularization.

35. (Previously presented) The method of Claim 41, wherein the compound is 2-methoxyestradiol.

36. (Previously presented) The method of Claim 30, wherein the compound is 2-methoxyestradiol.


37. (Previously presented) The method of Claim 31, wherein the compound is 2-methoxyestradiol.

38. (Previously presented) The method of Claim 41, wherein the neovascularization is ocular neovascularization and the compound is 2-methoxyestradiol.

39. (Previously presented) The method of Claim 30, wherein the neovascularization is ocular neovascularization and the compound is 2-methoxyestradiol.

40. (Previously presented) The method of Claim 31, wherein the neovascularization is ocular neovascularization and the compound is 2-methoxyestradiol.

41. (Currently amended) A method of inhibiting neovascularization in a mammal, comprising administering to the mammal a neovascularization-inhibiting amount of a compound of the formula:



wherein, Ra is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₂, -Br, or -I and wherein, in each formula set forth above, each R₁ and R₂ independently is -H, or a substituted or unsubstituted alkyl, alkenyl or alkynyl group of up to 6 carbons; and
provided that Ra is not H.